Home
November 2008 December 2008 January 2009
Su Mo Tu We Th Fr Sa
Week 49 1 2 3 4 5 6
Week 50 7 8 9 10 11 12 13
Week 51 14 15 16 17 18 19 20
Week 52 21 22 23 24 25 26 27
Week 1 28 29 30 31

Percent Tumor Involvement and Risk of Biochemical Progression After Radical Prostatectomy - Abstract Show Comments PDF Print E-mail
  
Friday, 20 June 2008

Division of Urologic Surgery (ENR, LS, JWM, SJF), Duke Prostate Center, Durham, North Carolina.

Percent tumor involvement has been associated with biochemical progression in organ confined disease, although its role in predicting outcome in men with more advanced disease pathology is unclear. We hypothesized percent tumor involvement may be a good correlate of outcome in all stages of prostate cancer.

We examined the association between percent tumor involvement in the radical prostatectomy specimen and the outcome measures of pathological stage and biochemical progression using multivariate logistic regression and Cox proportional hazards analysis, respectively, in 2,220 patients from the Duke Prostate Center radical prostatectomy database.

On multivariate analysis, percent tumor involvement significantly predicted the risk of positive margins (p <0.001), extracapsular extension (p <0.001), seminal vesicle invasion (p <0.001) and biochemical progression (HR 1.16, 95% CI 1.01-1.33, p = 0.035). The percent tumor involvement cut points of 5% or less, 6% to 20%, 21% to 50% and greater than 50% significantly separated men in groups with differing biochemical progression risk (p <0.001). In addition, these cut points were further able to stratify men among those with organ confined margin negative disease (p <0.001), either positive margins or extracapsular extension (p <0.001), and those with seminal vesicle invasion (p = 0.02).

Percent tumor involvement was a significant predictor of biochemical progression and was able to further stratify men who were already assigned to narrowly defined pathological groups. If confirmed in other studies, percent tumor involvement may enable the clinician to identify the high risk patient who stands to benefit the most from adjuvant therapy.

Written by
Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ.

Reference
J Urol. 2008 Jun 11. Epub ahead of print.
doi:10.1016/j.juro.2008.04.017

PubMed Abstract
PMID:18554662

UroToday.com Prostate Cancer Section

 

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >

Member's Section

Login

Sign Up

FAQ

Quick Search